Patents Assigned to Japan Chemical Research Co., Ltd.
-
Patent number: 5173415Abstract: A membrane filter of 0.025 to 0.05 .mu. in pore size is treated by passing the solution of a water-soluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, gelatin or the like through the membrane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hormone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active substance can be removed.Type: GrantFiled: January 14, 1991Date of Patent: December 22, 1992Assignee: Japan Chemical Research Co., Ltd.Inventors: Hajime Hiratani, Jun Tateishi, Tetsuyuki Kitamoto
-
Patent number: 4946785Abstract: The thermal degradation of urokinase in an aqueous solution is suppressed by heating an aqueous solution containing urokinase in the presence of citric acid or a water-soluble salt thereof such as sodium, potassium or lithium citrate at about 60.degree. C. for about 10 hours.Type: GrantFiled: June 17, 1988Date of Patent: August 7, 1990Assignee: Japan Chemical Research Co., Ltd.Inventors: Hajime Hiratani, Satoshi Nishimuro, Koichiro Nakanishi, Masaichi Ota, Hiroshi Matsumoto
-
Patent number: 4780209Abstract: Two components, trypsin and kallidinogenase, in human urine are concentrated simultaneously by allowing human urine at neutral pH, collecting bubbles thus formed to obtain the concentrate of the two components, adjusting the concentrate to weak acidity, contacting the acidified concentrate with chitosan to allow the two components to be adsorbed onto chitosan, eluting the components from the adsorbent with aqueous ammonia solution, and neutralizing and heating the eluate at about 60.degree. C. for about 10 hours to make the eluate virus-free, followed by separating the components from the eluate.Type: GrantFiled: October 2, 1987Date of Patent: October 25, 1988Assignee: Japan Chemical Research Co., Ltd.Inventors: Yoshikazu Yuki, Koichiro Nakanishi, Hajime Hiratani
-
Patent number: 4676983Abstract: A tumor cytostatic-cytocidal factor is produced by disrupting platelets, extracting the disrupted platelets with an acidic aqueous solution or an acidic water-organic solvent mixture, and, after gel filtration, if desired, to separate a fraction having an estimated molecular weight of 10,000 to 20,000 and having tumor cell growth inhibiting activity, subjecting said extract or said fraction to chromatography to isolate a cytostatic fraction having a molecular weight of 10,000 to 20,000 and an isoelectric point of 9.0 to 10.0, giving a positive nihidrin reaction and being such that it is deactivated by trypsin but not deactivated by heating in physiological saline solution at 60.degree. C. for 30 minutes or contacting at room temperature with 0.2N hydrochloric acid for 60 minutes or 70% formic acid for 30 minutes.Type: GrantFiled: March 21, 1986Date of Patent: June 30, 1987Assignee: Japan Chemical Research Co., Ltd.Inventors: Toyohiko Nishimura, Hajime Hiratani
-
Patent number: 4665161Abstract: Crude HCG is purified by extracting with a neutral or weakly basic aqueous solution containing lower aliphatic alcohol and soluble salt, adding lower aliphatic alcohol to the extracted solution to form precipitates and the precipitates containing high purity of HCG are collected. This precipitates can be further purified by dissolving in a buffer solution, contacting the solution with a weak anion exchanger and eluting the exchanger with said buffer solution containing added salt.Type: GrantFiled: April 21, 1986Date of Patent: May 12, 1987Assignee: Japan Chemical Research Co., Ltd.Inventors: Yoshikazu Yuki, Toyohiko Nishimura, Hajime Hiratani
-
Patent number: 4609546Abstract: A composition wherein a physiologically active polypeptide or a glycoprotein of human origin, for instance, urokinase, kallikrein or leukocyte interferon, is coupled to a polyoxyethylene-polyoxypropylene copolymer. The composition is effective in the human body for a prolonged period of time.Type: GrantFiled: June 23, 1983Date of Patent: September 2, 1986Assignee: Japan Chemical Research Co., Ltd.Inventor: Hajime Hiratani
-
Patent number: 4528186Abstract: A method for producing a human epidermal growth factor in high yield and high purity by adding particles of an aluminum or magnesium silicate of the formula z.2 (or 6) SiO.sub.2.xH.sub.2 O where Z is Al.sub.2 O.sub.3 or 2MgO and x is the number of water molecules in each molecule of the compound, to human urine under neutral to acid conditions to adsorb the factor on the particles and then eluting the factor with an alkaline solution.Type: GrantFiled: June 9, 1983Date of Patent: July 9, 1985Assignee: Japan Chemical Research Co., Ltd.Inventors: Toyohiko Nishimura, Naomi Uchida, Hajime Hiratani
-
Patent number: 4510248Abstract: Human urinary kallikrein is concentrated and purified by the following procedures; (a) Human urine is contacted with chitosan, a high molecular agglutinant obtained from chitin, at a pH from 4.0 to 7.0, thereby kallikrein is adsorbed on the chitosan and (b) kallikrein is eluted from the chitosan with an aqueous alkaline solution having a pH from 8.0 to 12.0.Type: GrantFiled: June 29, 1983Date of Patent: April 9, 1985Assignee: Japan Chemical Research Co., Ltd.Inventors: Koichiro Nakanishi, Hajime Hiratani
-
Patent number: 4500514Abstract: Human urine kallikrein dissolved in water is made heat-stable by the addition of a citric acid salt such as sodium citrate, so that an aqueous solution containing the kallikrein and the citric acid salt can be sterilized at 60.degree. to 70.degree. C.Type: GrantFiled: December 1, 1983Date of Patent: February 19, 1985Assignee: Japan Chemical Research Co., Ltd.Inventors: Koichiro Nakanishi, Hajime Hiratani
-
Patent number: 4468344Abstract: Gastric acid secretion inhibiting substance obtainable from mammalian urine by conventional method is fractionated into the first and second components by gel filtration, adsorption and desorption on ion exchanger or electrophoresis detecting each component by biological test methods. The activities of the two components differ from each other in the biological tests.The first component is a glucoprotein-like substance of M.W. 100,000 and the second component is a peptide-like substance of M.W. about 6,000.Type: GrantFiled: January 27, 1983Date of Patent: August 28, 1984Assignee: Japan Chemical Research Co., Ltd.Inventors: Hajime Hiratani, Naomi Uchida, Toyohiko Nishimura
-
Patent number: 4397840Abstract: The invention provides a novel erythropoietin product prepared from the urine of healthy human but exhibiting no inhibitory effect against erythropoiesis as is the most disadvantageous problem in the product prepared from the urine of healthy human. The method for the preparation of such a product comprises adsorbing the crude erythropoietin product obtained from the urine of healthy human on to a weakly basic anion exchanger from a neutral or weakly acidic aqueous solution containing 0.1 to 0.2 mole per liter of an inorganic neutral salt such as sodium chloride and then eluting the thus adsorbed ingredients with an aqueous eluant solution containing from 0.5 to 0.7 mole per liter of an inorganic neutral salt.Type: GrantFiled: March 3, 1982Date of Patent: August 9, 1983Assignees: Ajinomoto Co., Inc., Japan Chemical Research Co., Ltd.Inventors: Kenji Takezawa, Hajima Hiratani
-
Patent number: 4303650Abstract: The invention provides a novel process for the production of erythropoietin, which is a promising medicine for curing anemia, from human urine containing the same. The inventive method comprises adjusting the pH value of the urine in the range from 6 to 8, if the pH value of the urine is out of this range, and contacting the thus pH-controlled urine with a specific adsorbent so as that the erythropoietin is selectively adsorbed on the adsorbent. The adsorbed erythropoietin is then eluted out by use of an eluant solution to give the product in a partially purified form.Type: GrantFiled: October 2, 1980Date of Patent: December 1, 1981Assignees: Ajinomoto Co., Inc., Japan Chemical Research Co., Ltd.Inventors: Kenji Takezawa, Hajime Hiratani